Skip directly to content


2018 | 2017 |2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992

Is Shorter Better? Understanding the Shorter Regimen for Treating Drug-Resistant Tuberculosis
March 12 – Confused about the shorter regimen for treating Multidrug-resistant TB (MDR-TB)? We were too, so we worked with DR-TB STAT on a brief to understand its pros and cons.

Securing a Tuberculosis-Free Future through the Visionary Research of the CDC’s Tuberculosis Trials Consortium
January 10, 2018 
The Tuberculosis Trials Consortium (TBTC) is a global leader in research and development for better tools to prevent, diagnose, and treat tuberculosis (TB). Housed within the U.S. Centers for Disease Control and Prevention (CDC), the TBTC conducts clinical research of high public health relevance and is key to strengthening domestic and global campaigns to eliminate TB. TBTC studies have produced several notable breakthroughs, including a shorter regimen for preventing TB (3HP) using isoniazid and rifapentine.

HIV Cure Information Sheet
December 14, 2017 – A TAG information sheet on the current state of research into curing HIV infection.

TAGline Fall 2017

December, 2017 – TAG's progress on the fight to end HIV/AIDS, viral hepatitis, and tuberculosis.

The Ascent Begins: Tuberculosis Research Funding Trends, 2005-2016
November 8, 2017 – The world spent $726 million on tuberculosis (TB) research in 2016, marking the first time annual spending has exceeded $700 million since TAG began tracking funding in 2005. Although this figure is $105 million above 2015 levels, it remains woefully inadequate when judged against the innovation gaps holding back the TB response and the ambitious global goals to end the TB epidemic by 2030.

End the Epidemic Resources: Southern States EtE Meeting Summary and FAQs
November 2, 2017 – One thing is abundantly clear: We can’t end the epidemic in the U.S. if we don’t end it in the South. In May, TAG, the Southern AIDS Coalition, the Southern HIV/AIDS Strategy Initiative, Sisterlove, AIDS Alabama, and the National Alliance of State and Territorial AIDS Directors (NASTAD) held a consultation with more than 40 community advocates and key stakeholders from across the Deep South to assess the major challenges and opportunities for EtE planning. Several key findings from that meeting can be found in a summary report.

HIV Research in the Era of PrEP: The Implications of TDF/FTC for Biomedical Prevention Trials
September 27, 2017 – The effectiveness of pre-exposure prophylaxis (PrEP) with the antiretroviral drug combination TDF/FTC (Truvada) raises questions regarding the design and conduct of trials of other candidate biomedical HIV prevention interventions, such as vaccines, passive immunization and alternative forms of PrEP.

An Activists Guide to the TB LAM Test
September 11, 2017 – As tuberculosis (TB) has risen to become the leading infectious killer of people living with HIV (PLHIV), diagnostic tests such as the TB LAM test are critically important to ensure diagnosis of TB quickly for this vulnerable population. An Activist's Guide to the TB LAM Test provides important messaging and strategies to support in-country LAM advocacy and activism.

TAG’s Annual Pipeline Report: Promising New HIV, TB & HCV Drugs and Diagnostics
July 18, 2017 – Treatment Action Group (TAG) announces the launch of its annual research and development landscape analysis: The Pipeline Report: Drugs, Diagnostics, Vaccines, Preventive Technologies, Research Toward a Cure, and Immune-Based and Gene Therapies in Development. our 2017 report continues to demonstrate the significant yields of drugs and biologics research and the advancement of breakthrough technologies that aim to detect, prevent, treat or cure HIV, tuberculosis (TB) and hepatitis C virus (HCV).

TAG's 2016 Annual Report
June 14, 2017 – Today more than ever, TAG’s work is vital. TAG’s passionately dedicated, deeply informed staff have been unstinting in their efforts to speed up research and high-quality prevention, treatment, and care programs for people living with HIV, hepatitis C virus (HCV), or tuberculosis (TB), and for those most at risk of acquiring these infections.

TAGline Spring 2017